

Haimanot Wasse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/361763/publications.pdf>

Version: 2024-02-01

51
papers

2,206
citations

236925

25
h-index

214800

47
g-index

52
all docs

52
docs citations

52
times ranked

2470
citing authors

#	ARTICLE	IF	CITATIONS
1	Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. American Journal of Kidney Diseases, 2002, 40, 90-103.	1.9	199
2	Neighborhood Poverty and Racial Disparities in Kidney Transplant Waitlisting. Journal of the American Society of Nephrology: JASN, 2009, 20, 1333-1340.	6.1	175
3	Risk Factors for Incident Stroke among Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 2623-2631.	6.1	156
4	Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney International, 2003, 64, 1455-1461.	5.2	120
5	Frequency of Swing-Segment Stenosis in Referred Dialysis Patients With Angiographically Documented Lesions. American Journal of Kidney Diseases, 2008, 51, 93-98.	1.9	115
6	Medicare Costs Associated With Arteriovenous Fistulas Among US Hemodialysis Patients. American Journal of Kidney Diseases, 2018, 72, 10-18.	1.9	107
7	High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. American Journal of Clinical Nutrition, 2012, 96, 672-679.	4.7	97
8	Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 501-512.	4.5	83
9	Inflammation, Oxidation and Venous Neointimal Hyperplasia Precede Vascular Injury from AVF Creation in CKD Patients. Journal of Vascular Access, 2012, 13, 168-174.	0.9	81
10	Association of Initial Hemodialysis Vascular Access with Patient-Reported Health Status and Quality of Life. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 708-714.	4.5	75
11	Parathyroidectomy rates among United States dialysis patients: 1990-1999. See Editorial by Goodman, p. 335. Kidney International, 2004, 65, 282-288.	5.2	73
12	Achieving the Goal of the Fistula First Breakthrough Initiative for Prevalent Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 57, 78-89.	1.9	71
13	Predictors of Delayed Transition From Central Venous Catheter Use to Permanent Vascular Access Among ESRD Patients. American Journal of Kidney Diseases, 2007, 49, 276-283.	1.9	69
14	Treatment Center and Geographic Variability in Pre-ESRD Care Associate with Increased Mortality. Journal of the American Society of Nephrology: JASN, 2009, 20, 1078-1085.	6.1	67
15	High-Output Heart Failure: How to Define It, When to Treat It, and How to Treat It. Seminars in Nephrology, 2012, 32, 551-557.	1.6	58
16	Arteriovenous Fistula Use Is Associated with Lower Cardiovascular Mortality Compared with Catheter Use among ESRD Patients. Seminars in Dialysis, 2008, 21, 483-489.	1.3	53
17	Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. American Journal of Clinical Nutrition, 2012, 95, 522-528.	4.7	51
18	Patient Awareness and Initiation of Peritoneal Dialysis. Archives of Internal Medicine, 2011, 171, 119.	3.8	47

#	ARTICLE	IF	CITATIONS
19	Racial and Gender Differences in Arteriovenous Fistula Use among Incident Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2010, 32, 234-241.	3.1	43
20	Falls among hemodialysis patients: potential opportunities for prevention?. <i>CJ: Clinical Kidney Journal</i> , 2014, 7, 257-263.	2.9	41
21	Catheter-Related Mortality among ESRD Patients. <i>Seminars in Dialysis</i> , 2008, 21, 547-549.	1.3	39
22	25-hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients. <i>BMC Nephrology</i> , 2011, 12, 24.	1.8	36
23	Impact of Mast Cell Chymase on Renal Disease Progression. <i>Current Hypertension Reviews</i> , 2012, 8, 15-23.	0.9	33
24	Vitamin D supplementation in pre-dialysis chronic kidney disease. <i>Dermato-Endocrinology</i> , 2012, 4, 118-127.	1.8	29
25	Vascular Mapping: Does It Help To Maximize Fistulae Placement?. <i>Advances in Chronic Kidney Disease</i> , 2009, 16, 316-320.	1.4	26
26	Geographic Concentration of Poverty and Arteriovenous Fistula Use among ESRD Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1776-1782.	6.1	23
27	Increased Plasma Chymase Concentration and Mast Cell Chymase Expression in Venous Neointimal Lesions of Patients with CKD and ESRD. <i>Seminars in Dialysis</i> , 2011, 24, 688-693.	1.3	22
28	Predictors of Central Venous Catheter Use at the Initiation of Hemodialysis. <i>Seminars in Dialysis</i> , 2008, 21, 346-351.	1.3	19
29	Very High-dose Cholecalciferol and Arteriovenous Fistula Maturation in ESRD: A Randomized, Double-blind, Placebo-Controlled Pilot Study. <i>Journal of Vascular Access</i> , 2014, 15, 88-94.	0.9	19
30	Metabolic Changes in Peripheral Blood Mononuclear Cells Isolated From Patients With End Stage Renal Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 629239.	3.5	19
31	ASDM Clinical Case Focus: Persistent Left Superior Vena Cava: Diagnosis and Implications for the Interventional Nephrologist. <i>Seminars in Dialysis</i> , 2006, 19, 540-542.	1.3	18
32	ASDIN white paper: Assessment and management of hemodialysis access-induced distal ischemia by interventional nephrologists. <i>Journal of Vascular Access</i> , 2020, 21, 543-553.	0.9	18
33	Patient selection, education, and cannulation of percutaneous arteriovenous fistulae: An ASDIN White Paper. <i>Journal of Vascular Access</i> , 2020, 21, 810-817.	0.9	18
34	Efficacy and safety associated with the use of the Surfacor [®] Inside-Out [®] Access Catheter System: Results from a prospective, multicenter Food and Drug Administration-approved Investigational Device Exemption study. <i>Journal of Vascular Access</i> , 2021, 22, 141-146.	0.9	17
35	Chronic Central Venous Access: From Research Consensus Panel to National Multistakeholder Initiative. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 461-469.	0.5	15
36	Vitamin D Therapy in Kidney Disease: More Vitamin D Is Necessary. <i>American Journal of Kidney Diseases</i> , 2014, 64, 667-669.	1.9	14

#	ARTICLE	IF	CITATIONS
37	Place of Percutaneous Fistula Devices in Contemporary Management of Vascular Access. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 938-940.	4.5	13
38	Accumulation of retained nonfunctional arteriovenous grafts correlates with severity of inflammation in asymptomatic ESRD patients. Nephrology Dialysis Transplantation, 2013, 28, 991-997.	0.7	7
39	Vessel Mapping for Dialysis Access Planning. Seminars in Dialysis, 2017, 30, 305-308.	1.3	7
40	ASDIN white paper: Management of cephalic arch stenosis endorsed by the American Society of Diagnostic and Interventional Nephrology. Journal of Vascular Access, 2023, 24, 358-369.	0.9	7
41	Risk for Progression to ESRD. Journal of the American Society of Nephrology: JASN, 2006, 17, 2092-2093.	6.1	6
42	ESRD patients using permanent vascular access report greater physical activity compared with catheter users. International Urology and Nephrology, 2013, 45, 199-205.	1.4	6
43	Increasing Physician Knowledge About the Diagnosis and Management of CKD: How Can We Help Primary Care Providers?. American Journal of Kidney Diseases, 2009, 54, 187-190.	1.9	4
44	Factors related to patient selection and initiation of peritoneal dialysis. Journal of Vascular Access, 2017, 18, S39-S40.	0.9	3
45	Cerebral hyperperfusion and other consequences of hemodialysis central vein catheters. Journal of Vascular Access, 2017, 18, S82-S83.	0.9	3
46	Association Between Type of Vascular Access Used in Hemodialysis Patients and Subsequent Kidney Transplant Outcomes. Kidney Medicine, 2019, 1, 383-390.	2.0	3
47	Reduced myocardial blood flow reserve in kidney transplant candidates may hamper risk stratification. Journal of Nephrology, 2021, 34, 197-209.	2.0	1
48	How I Do It: Thrombosed Arteriovenous Graft Resulting from a Crushed Stent in a Nonambulatory Hemodialysis Patient. Seminars in Dialysis, 2008, 21, 178-179.	1.3	0
49	Diagnostic and Interventional Nephrology. , 2010, , 1043-1052.		0
50	Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. FASEB Journal, 2013, 27, 46.3.	0.5	0
51	Vascular Suitability for an Endovascular Arteriovenous Fistula: Getting Beyond the Velvet Rope. Kidney360, 2022, 3, 201-203.	2.1	0